kabutan

MediciNova,Inc.(4875) Summary

4875
TSE Standard
MediciNova,Inc.
226
JPY
+7
(+3.20%)
May 1, 3:30 pm JST
1.43
USD
May 1, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
Yield
ー%
Margin Trading Ratio
Stock Price
May 1, 2026
Opening May 1, 9:00 am
217 JPY 1.38 USD
Previous Close Apr 30
219 JPY 1.36 USD
High May 1, 3:24 pm
226 JPY 1.43 USD
Low May 1, 9:00 am
217 JPY 1.38 USD
Volume
25,300
Trading Value
6.00M JPY 0.04M USD
VWAP
222.88 JPY 1.42 USD
Minimum Trading Value
22,600 JPY 143 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
60
Liquidity & Number of Trades
As of May 1, 2026
Liquidity
Mid
1-Year Average
191
1-Year High Nov 5, 2025
3,850
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 78,400
Apr 17, 2026 0 78,200
Apr 10, 2026 0 78,200
Apr 3, 2026 0 76,800
Mar 27, 2026 0 76,600
Company Profile
MediciNova, Inc. is a US-based pharmaceutical development venture focusing on treatments for conditions such as acute asthma attacks.
Sector
Pharmaceuticals
MediciNova, Inc. is a pharmaceutical development company headquartered in the United States, specializing in the development of novel therapeutics for serious diseases. Its lead development product, MN-166 (ibudilast), is being developed for indications including ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence, alcohol use disorder, and Long-COVID. MN-001 (tipelukast) is being developed for non-alcoholic fatty liver disease and idiopathic pulmonary fibrosis. Additionally, a treatment for phenylketonuria is included in the development pipeline. The company has received Fast Track and Orphan Drug designations from the US FDA for several of its development products, indicating a promising development pipeline.